{"prompt": "['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Statistical Methods (Continued):', 'Pharmacokinetic:', 'Individual concentrations of rovalpituzumab tesirine ADC will be tabulated and summarized for subjects', 'treated with the active regimen and summary statistics provided. The incidence of ATA will be', 'summarized.', 'Biomarkers:', 'Biomarkers will be measured at baseline and post-treatment and analyses performed to identify markers', 'associated with rovalpituzumab tesirine response, pharmacodynamics, PK, or safety.', 'Safety:', 'The safety of rovalpituzumab tesirine will be assessed by evaluating the study drug exposure, adverse', 'events, all deaths, as well as changes in laboratory determinations and vital sign parameters.', 'Section 1.3 List of Abbreviations and Definition of Terms', 'Subsection Abbreviations', 'Add:', 'LD SCLC', 'Limited-stage disease small cell lung cancer', 'Section 3.3 Rovalpituzumab Tesirine', 'Last paragraph Previuosly read:', 'In a Phase 1 study (SCRX16-001), rovalpituzumab tesirine dosed at 0.2 - 0.4 mg/kg', 'exhibited encouraging efficacy in recurrent SCLC, achieving a 31% (8/26) and 85%', '(22/26) central review-adjudicated confirmed objective response rate (ORR) and clinical', 'benefit rate (CBR), respectively, in subjects whose tumors expressed DLL3 in > 50% of', 'cells. Median overall survival was 7.7 months in DLL3 > 50% subjects at all dose levels,', 'with a 1-year survival rate of 30%.9 Therefore, rovalpituzumab tesirine appears to be an', 'active anti-cancer therapy.', 'Has been changed to read:', 'In the Phase 1 first in human study of rovalpituzumab tesirine (Study SCRX16-001), the', 'best overall response (confirmed) for all SCLC subjects (dose escalation, retreatment, and', 'maintenance cohorts) was retrospectively assessed by the Independent Review Committee', '(IRC) by RECIST v1.1 criteria. The ORR (confirmed) was 16% (95% CI: 7.35,27.42),', '159']['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'with 12% achieving PR. The clinical benefit rate (CBR) was 59% (95% CI: 44.93,', '71.40). The median duration of response by the IRC was 1.7 months (95% CI: 0.03,', '3.06). The median progression-free survival by the IRC was 3.0 months (95% CI: 2.56,', '3.84), with a probability of progression-free survival at 12 weeks of 52% (95% CI: 39,', '63). The median overall survival was 4.3 months (95% CI: 3.22, 5.65). The probability', 'of overall survival at 12 weeks was 69% (95% CI: 52, 81). In DLL3-positive ( 1%', 'tumor cells staining positive for DLL3 with murine anti-DLL3 antibody assay) subjects,', 'the ORR was 23% (95% CI: 10.42, 40.14), and the CBR was 77% (95% CI: 59.86,', '89.58). A slightly higher ORR (27%) and CBR (87%) were observed in DLL3-high', '(> 50% tumor cells staining positive for DLL3 with murine anti-DLL3 antibody assay)', 'subjects.', 'In the Phase 2 Study SCRX001-002 (TRINITY) in patients with SCLC recurrent after at', 'least two systemic chemotherapy regimens, rovalpituzumab tesirine dosed at 0.3 mg/kg', 'every 6 weeks for two cycles (with an option for additional two cycles upon progression', 'occurring > 12 weeks after the second dose) resulted in the following:', 'In DLL3 high @ 75% tumor cells staining positive for DLL3 with VENTANA', 'Rabbit IHC (SP347) DLL3 assay) subjects, ORR of 14% per IRC assessment,', 'median OS of 5.7 months and median PFS of 3.8 months', 'In DLL3 high subjects, the clinical benefit rate was 74% with a median duration', 'of clinical benefit of 3.0 months per IRC assessment', 'Additionally, DLL3 positive (> 25% tumor cells staining positive for DLL3 with', 'VENTANA Rabbit IHC (SP347) DLL3 assay) and DLL3 high groups had comparable', 'response rates given highly overlapping populations where approximately 85% of DLL3', 'positive subjects were also DLL3 high', 'In December 2018, enrollment in Study M16-289 TAHOE (\"A Randomized, Open-Label,', 'Multicenter, Phase 3 Study of Rovalpituzumab Tesirine Compared with Topotecan for', 'Subjects with Advanced or Metastatic DLL3high Small Cell Lung Cancer (SCLC) who', 'have First Disease Progression During or Following Front-Line Platinum-Based', '160']\n\n###\n\n", "completion": "END"}